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Background:  Follicular cell-derived thyroid 
carcinomas harboring RET/PTC oncogenes are 
immunostimulatory and highly curable, despite 
activating RAS/BRAF/MEK/ERK and PI3K/AKT.  
Results:  RET/PTC oncoproteins associate with 
TRAFs to mediate cytokine production but not 
transformation. 
Conclusion:  The RET/PTC:TRAF pathway is 
functionally separable from the RET/PTC-induced 
MEK/ERK and PI3K/AKT pathways. 
Significance:  Understanding RET/PTC-mediated 
immunostimulation could provide new strategies 
for treating more aggressive forms of thyroid 
carcinoma.  
 
SUMMARY 
Thyroid carcinomas that harbor RET/PTC 
oncogenes are well differentiated, relatively 
benign neoplasms compared to those expressing 
oncogenic RAS or BRAF mutations despite 
signaling through shared transforming 
pathways.  A distinction, however, is that 
RET/PTCs induce immunostimulatory 
programs, suggesting that, in the case of this 
tumor type, the additional pro-inflammatory 
pathway reduces aggressiveness.  Here we 
demonstrate that pro-inflammatory programs 
are selectively activated by TRAF2 and TRAF6 
association with RET/PTC oncoproteins.  
Eliminating this mechanism reduces pro-
inflammatory cytokine production without 
decreasing transformation efficiency.  
Conversely, ablating MEK/ERK or PI3K/AKT 
signaling eliminates transformation but not 
pro-inflammatory cytokine secretion.  
Functional uncoupling of the two pathways 
demonstrates that intrinsic pro-inflammatory 
pathways are not required for cellular 
transformation and suggests a need for further 
investigation into the role inflammation plays in 
thyroid tumor progression. 
Inflammation can contribute to late phases of 
cancer progression by enhancing viability, 
angiogenesis and metastasis (1, 2).  The notion 
that inflammation can also be an important early 
event during neotransformation is based upon the 
positive correlation observed between pre-existing 
chronic inflammatory conditions and cancer 
incidence (1-3);  and the observed effects of anti-
inflammatory compounds modulating cancer 
development (4) Thus, it has been suggested that 
activation of the NF-κB family of transcription 
factors promotes mitogenicity by triggering 
cytokine secretion from neoplasia and 
inflammatory infiltrates while supporting tumor 
viability through inhibition of apoptotic pathways 
(5). Additionally, inflammatory infiltrates have the 
potential to induce reactive oxygen species and 
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such an oxidative environment could promote 
oncogenic mutations (6).  Yet, NF-κB itself is not 
an oncogene and tissue specific autoimmunity in 
the absence of cancer often exists in patients for 
extensive periods.  Therefore, the requirement for 
inflammation during initiation and early stages of 
tumorigenesis remains unclear (1).   
Papillary thyroid carcinoma (PTC), the most 
prevalent endocrine cancer worldwide (7), is 
particularly attractive for exploration of this issue.  
PTCs that progress to become more aggressive 
follicular cell-derived thyroid carcinomas 
(FDTC), such as follicular thyroid carcinoma  
(FTC) and anaplastic thyroid carcinoma (ATC) 
are generally associated with point mutations in 
RAS small GTPases or BRAF serine/threonine 
kinases, respectively (2, 8).  The more indolent 
PTCs are associated with radiation-induced 
RET/PTC oncogenes that encode fusions of the 
RET receptor kinase domain with one of several 
different dimerizing proteins, resulting in a 
constitutively active kinase (9).  The most 
prevalent RET/PTC isoforms are RET/PTC1 
(RP1) and RET/PTC3 (RP3) consisting of either 
H4/CCDC6 or ARA70/ELE1 as the respective N-
terminal dimerizing partner (10)(10)(10) (10-12). 
RET/PTC oncogenes activate both 
RAS/BRAF/MEK/ERK and PI3K/AKT pathways 
that are crucial for thyrocyte transformation (13-
15), yet are associated with a high cure rate and 
low tumor recurrence.  In contrast, the more 
aggressive FDTCs usually harbor oncogenic RAS 
or BRAF point mutations and are associated with a 
poorer prognosis and higher recurrence rate (2, 8).   
Notably, FDTC harboring RET/PTC 
oncogenes display an immunostimulatory profile 
(14, 15) and is associated with the development of 
autoimmune thyroiditis (16-21).  Conversely, the 
more aggressive and poorly differentiated FDTCs, 
expressing oncogenic RAS or BRAF point 
mutations, are characterized by tumor-promoting 
immune responses such as the infiltration of 
immunosuppressive macrophages (22).  Although 
the mechanistic basis for RET/PTC-induced 
immunostimulation is currently unclear, it is 
thought to involve members of both the classical 
and alternative pathways of NF-κB through the 
stabilization of NIK kinase (23-25). 
 
Since RET/PTC oncoproteins activate 
RAS/BRAF/MEK/ERK, PI3K/AKT, and NF-κB 
signal transduction pathways, this tumor type 
might be expected to be highly proliferative and 
readily progress to a less differentiated cancer 
such as anaplastic carcinoma.  However, 
RET/PTC-expressing PTCs tend to be rather 
indolent and expression in poorly-differentiated 
and anaplastic thyroid carcinomas are rare (26).  
Thus, in the case of PTC, one interpretation of this 
process is that the additional immunostimulatory 
program is detrimental to the progressing tumor.   
To resolve this conundrum, our primary goal was 
to determine whether proinflammatory cytokine 
release and cellular transformation proceed along 
the same signaling pathways, or whether the two 
processes are functionally distinct and separable.  
The latter would permit investigation of whether 
the RET/PTC-induced proinflammatory program 
is necessary for transforming events as well as 
exploration of the mechanistic link between 
RET/PTC expression and NF-κB activation. The 
results of our investigations provide insight into 
the early stages of thyroid oncogenesis that could 
influence future approaches to the treatment of all 
types of FDTC. 
 
Experimental Procedures 
 
Chemical Reagents:  All cell culture and 
chemical reagents were purchased from Sigma 
unless stated otherwise. 
Cloning: mRP3.51 (RP3) was previously 
constructed and cloned into a bacterial expression 
vector (27). To perform the following studies RP3 
was excised from the pET29a vector and cloned 
into the mammalian expression vectors Rc/CMV 
and MSCV.IRES.GFP.  A Kozak consensus and a 
TAA stop sequence were placed 5’ and 3’ of the 
RP3 cDNA.  All RP3 mutants were created by 
site-directed mutagenesis using Quikchange II 
(Stratagene) according to manufacturer’s 
instructions.  MSCV.IRES.mRFP was created by 
excising the GFP sequence and replacing it with 
the sequence for monomeric RFP.  The sequences 
encoding TRAF2 and TRAF6 blocking peptides 
(T2pep and T6pep) and control peptides (T2cntl 
and T6cntl) were synthesized by IDT, amplified 
by PCR and cloned into MSCV.IRES.mRFP. 
 4 
 
Cell Culture: TPC-1 and PCCL3 cells were 
kindly provided previously by Dr. Massimo 
Santoro.  NIH-3T3 (kindly provided by Dr. 
Tschiclis, Tufts University), 293T (ATCC), and 
TPC-1 cell lines were maintained in DMEM 
media with 10% FBS (D10).  The rat PCCL3 
thyroid cell line was maintained in F12 media 
containing 5x10-3 IU/ml bovine TSH, 5 µg/ml 
bovine insulin, 10 ng/ml Gly-His-Lys, 
somatostatin 10 ng/ml, apo-transferin 5 µg/ml, 10 
nM hydrocortisone, and 10% FBS (F12+).  
PCCL3 cells require thyroid stimulating hormone 
(TSH) for cell growth under basal conditions and 
exhibit TSH-independent growth upon expression 
of RET/PTC.  However, since removing TSH can 
alter the ability of thyrocytes to produce 
inflammatory cytokines (28-30), all PCCL3 
treatments were maintained in the same culture 
conditions.  For all experiments PCCL3 cells were 
treated in a 1:1 ratio of F12 media and D10.  All 
cells were maintained in a 37oC incubator at 9% 
CO2.  For the generation of stable lines: 
Retrovirus was prepared by co-transfecting 293T 
cells with pCL-Eco and indicated 
MSCV.IRES.GFP or MSCV.IRES.mRFP 
constructs with Fugene 6 (Roche). At 24 hr post-
transfection, fresh medium was replaced and viral 
supernatant was collected at 24, 48, and 72hr.  For 
viral transduction, cells were plated at 5x10^4 
cells/well in 6-well plates and treated with pre-
filtered viral supernatant diluted 1:2 in DMEM 
containing 10% FBS and 8 µg/ml polybrene.  At 
24 hr post-transduction viral supernatant was 
replaced with fresh 10% media and sorted for GFP 
or monomeric RFP expression on day 3.  For 
maintenance of cell lines: NIH-3T3 transductants 
were maintained in D10 while all PCCL3 
transductants were maintained in 1:5 ratio of 
F12+:D10.  TSH, insulin, Gly-His-Lys, 
somatostatin, apo-transferin, and hydrocortisone 
were all from Sigma.    U0126 (Cell Signaling 
Technology) was chosen based on its high 
selectivity to both MEK1 and MEK2 (versus 
PD098059 which inhibits MEK1), and used at 10 
µM at all indicated times based on previously 
published results (31).  LY294002 (Cell signaling 
Technology) was chosen based on its high 
selectivity to PI3K and used at 10 µM to 
demonstrate PI3K/AKT inhibition in the absence 
of apoptosis/toxicity (32, 33).  
Transient Transfection and siRNA knockdown:  
For cytokine analysis of PCCL3 cells, 105 
cells/well were plated in 6-well tissue culture 
plates.  The next day cells were transfected with 
Genejuice (EMD Chemicals) at a 3:3 ratio of 
reagent (µl):DNA (µg).  After 48 hr, total RNA 
(Machery-Nagel) or cytosolic protein was 
harvested for RT-PCR or western analysis.  For 
TRAF knockdown of TPC cells, TRAF2 siRNA 
and TRAF6 siRNA (Santa Cruz) were transfected 
at 25 nM with siRNAMAX (Invitrogen) and on 
day 2 was harvested for ELISA, RT-PCR, or 
western analysis or subsequently treated and 
harvested on day 4 as indicated. 
RT-PCR:  Total RNA was extracted using the 
Nucleospin RNA II kit (Macherey-Nagel). 
Reverse transcriptase-PCR was performed on 0.5-
2 µg of total RNA using Superscript II 
(Invitrogen) according to manufacturer’s 
instructions.  PCR was performed for 30 cycles at 
60oC. 
Western Blot Analysis and Immuno-
precipitations: All cells were lysed with 150 mM 
NaCl, 20 mM Tris-Cl, 1% Triton X 100, pH 7.2 
containing 1X HALT protease inhibitors with 
EDTA (Pierce) and 1X HALT phosphatase 
inhibitors (Pierce).  Lysates were quantified using 
BCA kit (Pierce).  For immuno-precipitation:  
Pre-cleared 500 µg total protein was incubated 
overnight with anti-RET antibody and Protein G-
sepharose beads (Pierce).  Subsequently, beads 
were washed with cell lysis buffer three times and 
eluted with 100 mM glycine (pH 2.7).  Eluted 
material was neutralized with 1M Tris pH 8.8, 
combined with 6X loading buffer, and run on 12% 
SDS-PAGE gel. For Western analysis: 10 µg of 
total protein was loaded onto a 12% SDS-
polyacrylamide gel.  Gels were blotted for 1 hr at 
100V onto nitrocellulose membranes (GE 
Biosciences) and blocked for 30 min with 5% 
milk/TBS + 0.1% Tween.   All blots were 
incubated overnight with the indicated antibody, 
washed and stained with anti-rabbit-HRP (Cell 
Signaling), donkey anti-mouse-HRP or donkey-
anti-goat-HRP (Jackson Immunoresearch).  All 
indicated antibodies were from Cell Signaling 
Technology aside from anti-phospho-RET (1062), 
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anti-RET (C-20), and anti-TRAF6 (H274) which 
were from SantaCruz Biotechnology. 
Macrophage Chemotactic Protein MCP-1 
ELISA:  A 96-well Maxisorp plate (Millipore) was 
coated at 2 mg/ml with anti-CCL2 antibody 
(eBioscience), overnight 4oC.  The plate was 
blocked with 1% BSA/PBS and cell culture 
supernatants were incubated in duplicate wells 
overnight at 4oC.  The next day, plates were 
washed with PBS/0.05% Tween 20 and incubated 
with biotinylated anti-CCL2 antibody 
(eBioscience) for 2 hr, 27oC, washed, stained with 
1:1000 Streptavidin-HRP (BD Bioscience) for 1 
hr, 27oC, and developed with 2 mg/ml OPD 
(Sigma) according to manufacturer’s instructions 
and visualized at 405 nm in a spectrophotometer 
(Victor2  by Wallac 1420 multilabel counter). 
Cell Proliferation: PCCL3 and TPC-1 
transductants were cultured in triplicate at 1000 
cells per well in 96-well flat bottom plates in D10 
media in the absence of hormones. Viable cells 
were counted daily by trypan blue exclusion. 
Soft Agar Assay: 5x103 stable GFP-expressing 
NIH-3T3 lines were suspended in 0.25% agarose 
in 1X MEM + 10% FBS with 1 X 
penicillin/streptomycin (Gibco) and 1X 
gentamicin (Gibco) and plated in triplicate over a 
layer of pre-set 0.5% agarose in 1X MEM + 10% 
FBS with 1 X penicillin/streptomycin and 1X 
gentamicin  in 6-well plates. 20 days after plating 
the cells were photographed and analyzed for 
colony number and size or stained for 1 hour at 
27oC with crystal violet in PBS and photographed 
over a light box. For quantification of colony size, 
5 photographs were taken per well using a Nikon 
Eclipse TE 2000-U camera attached to a confocal 
microscope.  1 photograph/1 cm2 block was taken 
using a grid that was partitioned in 1 cm2 sections 
was .  The longest length of the colonies was 
measured in µm using the NIS Elements Version 
2.3 program.  The sum of the number and length 
of the colonies was calculated per well and the 
mean and standard deviation of triplicate wells 
was calculated per condition (total of 15 
photographs taken per condition). 
 
RESULTS 
 
Chemical inhibition of PI3K and MEK1/2 
does not decrease RET/PTC-mediated cytokine 
induction.  Both RP1 and RP3 activate similar 
oncogenic and inflammatory programs (14, 15, 25, 
34) and this trait is attributed to the constitutively 
active C-terminal RET kinase domain that is 
shared by all RET/PTC variants (35, 36). 
Therefore, we utilized an immortalized rat thyroid 
cell line, PCCL3,  transiently transfected with RP3 
to examine early activation of proinflammatory 
cytokine transcription..  Early phase induction 
occurs within the first 48 hr of expression and 
drives ectopic production of MCP1 in abundant 
quantities and IL6 to a lesser extent (34).  To 
determine whether this early cytokine induction is 
dependent upon PI3K/AKT or MEK/ERK 
signaling, PCCL3 cells were transfected with the 
highly related mouse homologue of RP3 (RP3WT) 
and treated with selective pathway inhibitors.  As 
demonstrated in Fig. 1A, the PI3K inhibitor 
LY294002 (LY) or with the MEK1/2 inhibitor 
U0126 (U0) did not disrupt early transcriptional 
induction of MCP1 or IL6 by RP3.  As a control 
for protein expression, RP3K284M, which is devoid 
of all kinase activity (37, 38), was examined and 
demonstrated no increase in AKT, ERK, or 
proinflammatory cytokine activity.  Furthermore, 
RP3 transfected cells treated with LY or U0 and 
cells transfected with RP3K284M exhibited less cell 
scattering, indicative of increased cell 
mobilization, and less transformation when 
phenotypically compared to cells transfected with 
RP3WT (Fig. S1A).  The inhibition of DUSP6 
induction by U0 and activation of the sodium 
iodide symporter (NIS) expression by U0 and LY, 
demonstrate that the inhibitors were effective at 
disrupting their respective pathways (Fig. 1A).  
Furthermore, western blot analysis revealed that 
treatments with LY and U0 led to a dramatic 
decrease in phosphorylation of AKT and ERK, 
respectively (Fig. 1B).   
Similar experiments were then performed to 
determine the influence of the AKT and ERK 
pathways on late phase cytokine expression.  After 
long-term expression in thyrocytes, RET/PTC 
induces a milieu of proinflammatory cytokines 
that include MCP1, IL6, IL8, TNFα, IL1α, IL1β, 
CXCL10, M-CSF and GM-CSF (14).  The TPC-1 
cells line is derived from human papillary thyroid 
carcinoma, constitutively expresses RP1, and 
produces these same proinflammatory cytokines.  
TPC-1 cells treated with LY or U0 exhibited no 
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loss of MCP1, IL6, and TNFα transcript 
production after 48 hrs (Fig. 1C).  In fact, it 
appears that inhibition of ERK activity actually 
increases cytokine transcription.  This 
phenomenon was also observed at the protein level 
(Fig. S1C), suggesting that a potential negative 
feedback role of MEK/ERK exists to reduce 
RET/PTC-mediated late phase cytokine secretion. 
Again, these compounds effectively disrupted 
intended components in these signaling pathways 
as indicated by western blot analysis (Fig. 1D), 
reduced transformed phenotype, and decreased 
cell proliferation (Figs. S1B and S1D). We did 
observe decreased MCP-1 secretion from LY 
treated cells (Fig. S1C), however this decrease 
was attributable to a reduction in total cell number 
(Fig. S1D).  Together these results support the 
idea that ectopic cytokine secretion is a common 
feature of RET/PTC variants (14, 34), and support 
the notion that this genetic program is not 
dependent upon PI3K/AKT and MEK/ERK for 
early or late phases of cytokine secretion.     
Proinflammatory and mitogenic signaling 
pathways originate from distinct regions of the 
RP3 oncoprotein. The observation that RP3-
mediated early and late inflammatory programs 
are not dependent upon AKT and ERK signaling, 
led us to investigate whether the inflammatory and 
mitogenic pathways could be uncoupled through 
genetic approaches.  Mass spectrometric analysis 
had previously determined that at least 8 of 16 key 
tyrosine residues are autophosphorylated during 
RET activation (39), and RP3 contains all 8 
proposed signaling tyrosines.  Therefore, we 
generated a panel of YF substitutions and 
screened for the ability of these mutants to induce 
early cytokine production from PCCL3 cells.  One 
of these mutations, Y588F, is known to be needed 
for PI3K/AKT and RAS/BRAF/MEK/ERK 
signaling (40-43).  If functional separation is 
possible, a mutation could demonstrate 
proinflammatory activity in the absence of AKT or 
ERK activity.  Indeed, both RP3WT and RP3Y588F 
induced equal amounts of MCP-1 (Fig. 2A), 
indicating that the inflammatory pathway does not 
initiate from Y588.  Since it has been reported that 
Grb2 binds the Y622 site (44), although it does not 
appear to contribute to ERK activity (40),, we 
additionally tested a Y588F/Y622F double mutant 
and did not detect decreases in MCP1 production 
(Fig. 2B).  With respect to the reverse phenotype, 
(transformation without proinflammatory activity) 
three substitutions, RP3K284M, RP3Y431F, and 
RP3Y478F, resulted in ablation of early phase RP3-
induced MCP-1 production from transiently 
transfected PCCL3 cells (Fig. 2A).  This was 
somewhat expected for RP3K284M and RP3Y431F 
since both encode proteins with catalytically 
inactive kinase domains based on the crystal 
structure and biochemical analysis of RET (39, 
45).  In contrast, altered MCP-1 induction by 
RP3Y478F was not anticipated and the downstream 
effect of this mutation on other RP3 regulated 
signaling pathways was investigated by western 
blot analysis.  As shown in Fig. 2C, compared to 
the other mutations, RP3Y478F enabled activation of 
both AKT and ERK pathways to the same degree 
as RP3WT.  These findings prompted a closer 
evaluation of the protein interactions at or adjacent 
to the Y478 region. 
TRAF2 and TRAF6 associate with RP3 in a 
kinase-independent manner.  To identify potential 
candidates as binding partners at or near Y478, the 
full length sequences of human, mouse, and rat 
RP3 were screened online at the Eukaryotic Linear 
Motif (ELM) site (http://elm.eu.org/) (46) using 
protein structure, cell compartment (cytosol), and 
taxonomic (human, mouse, and rat) filters.  
Consequently, the sequence 482-487 
(GIPPERLF), adjacent to Y478, was identified as 
a potential binding site for TRAF6 and 560-564 
(SEEE) was designated as a site for TRAF2.  
TRAF2 and TRAF6 are members of the TRAF 
(TNF Receptor Associated Factor) family of E3 
ubiquitin ligases that initiate either classical or 
alternative NF-κB signaling cascades from TNFR 
family members, TLRs, and other cell surface 
receptors such as NGFR and TGFβR to promote 
proinflammatory cytokine production (47).  
The GIPPERLF site is situated within a 
surface soluble disordered loop (45) suggesting 
that this region is accessible to cytosolic binding 
partners, and the SEEE motif also appears to be 
located within disordered regions according to the 
ELM site and the online program GlobPlot 
(http://globplot.embl.de/) using Deleage/Roux or 
Russell/Linding set parameters (48).  To determine 
whether TRAF proteins associate with RET/PTC, 
293T cells were transiently transfected with RP3 
and cell lysates were subjected to 
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immunoprecipitation with an anti-RET antibody 
specific for the last 51 amino acids of the C-
terminus.   As shown in Fig. 3B, TRAF2 and 
TRAF6 co-precipitate with RP3WT without 
additional cross-linking indicating a specific 
association.  Additionally, TRAF2 and TRAF6 
binding to RP3Y588F is equivalent to that of RP3WT, 
while RP3Y478F exhibits decreased association to 
TRAF6 (Figs. 3C&D). Of note, TRAF2 and 
TRAF6 bind equally well to the kinase dead 
mutant, RP3K284M, indicating that binding is 
independent of kinase activity (Figs 3B-D)..  To 
determine the requirements for TRAF interaction, 
we created truncated mutants of RP3 (Fig. 3A).  
RP3∆N lacks the autodimerizing N-terminal 
segment (residues 1-238) and RP3∆TK2 lacks the 
second tyrosine kinase domain of RET (residues 
338-589) in which the TRAF-binding motifs are 
predicted to reside.  No association was detected 
with RP3∆TK2, while association of TRAF2 and 
TRAF6 was detectable with RP3∆N, only after 
prolonged exposure of the blot but beyond the 
linear range of detection compared to the RP3WT 
signal (unpublished data) (Fig. 3B).  These 
findings suggest that, although TRAF binding is 
independent of kinase function, TRAF association 
is still dependent upon RP3 dimerization (model in 
Fig. 7).  Furthermore, the absence of TRAF 
association with RP3∆TK2 suggests that TRAF or 
TRAF-binding adaptor proteins associate within 
residues 338-589.  We confirmed the specificity of 
the association by examining the endogenous 
interaction of TRAF2 and TRAF6 to RP1 in the 
TPC-1 cell line.  Fig. 3G demonstrates that 
immunoprecipitation of RP1 can pull down both 
TRAF2 and TRAF6; suggesting that TRAF 
association is most likely occurring in the C-
terminus derived from RET. 
To dissect the specificity of TRAF2 and 
TRAF6 binding, the putative sites were altered 
from SEEE to SEAA (RP3T2mut) and GIPPERLF to 
GIQPARLA (RP3T6mut).  Examination of RP3T2mut 
showed decreased binding to TRAF2 compared to 
RP3WT with no effect on TRAF6 association (Fig. 
3D), while RP3T6mut demonstrated decreased 
binding to both TRAF2 and TRAF6 (Fig. 3E).  In 
contrast to the ∆N and ∆TK2 truncations, none of 
the tested mutations completely ablated TRAF 
association, suggesting that there are additional 
points of contact within the binding sites or that 
RP3 contains additional binding sites for TRAFs 
and/or TRAF-associated adaptors.  Overall these 
findings further support the idea that 
proinflammatory signaling is initiated at TRAF-
binding sites through a mechanism that is distinct 
from Y588-mediated pathways. 
The RP3-induced TRAF-mediated production 
of proinflammatory cytokines is independent of the 
RAS/BRAF/MEK/ERK and PI3K/AKT pathways. 
Since TRAF oligomerization is known to activate 
NF-κB family members and subsequent cytokine 
induction, we investigated whether TRAF 
signaling was responsible for production of 
cytokines from RET/PTC-transformed cells.  As 
shown in Figs. 4A-C, siRNA knockdown of either 
TRAF2 or TRAF6 substantially decreased MCP1 
production.  Induction of other cytokines was also 
reduced, GMCSF > IL8 > IL6 > TNFα.  This 
change in inflammatory profile was regulated 
mainly, if not entirely, at the transcriptional level 
as demonstrated by RT-PCR (Figs. 4A-B).  To 
confirm the reduction of cytokine secretion, 
supernatants were harvested from TPC-1 cells on 
day 2 and day 4 after siRNA treatment and tested 
in a specific MCP1 ELISA.   As shown in Fig. 4C, 
MCP1 protein secretion by TRAF siRNA-treated 
cells was greatly reduced in a time dependent 
manner compared to siRNA control.   
Additionally, we examined the ability of 
TRAF-inhibiting peptide sequences to knockdown 
cytokine secretion over a longer period of time.  
The TRAF2 peptide sequence designed from 
CD40, AYPIQETA (T2pep), and the TRAF6 
sequence designed from RANK, APTEDEYA 
(T6pep), as well as their controls (AYAIAATA 
and AATADAYA) were overexpressed using 
MSCV.IRES.mRFP viral vectors and stable 
transductants were selected by cell sorting for 
RFP.  Fig. 4D demonstrates that inhibition of 
TRAF2 oligomerization via overexpression of the 
TRAF2 binding motif greatly reduce cytokine 
expression in TPC-1 cells.  Overexpression of 
T6pep did not reduce MCP1 induction to the same 
extent as T2pep and may reflect a decreased 
affinity of this peptide for its target. 
We further examined the cytokine profile of 
PCCL3 cells stably expressing the RP3 mutants.  
As observed in Fig. 4E, it appears that ablation of 
MCP1 production was not maintained with 
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sustained expression of RP3Y478F or RP3T2mut; 
however, this is in contrast to the RP3T6mut, in 
which the long-term production of MCP1 was 
greatly reduced.  This result may reflect the fact 
that the RP3Y478F or RP3T2mut mutations do not 
completely ablate TRAF binding although the 
association is reduced. 
We next determined whether TRAF2 or 
TRAF6 contribute to either AKT or ERK 
signaling.  As predicted by our original findings, 
TPC-1 cells treated with siRNA specific for 
TRAF2 or TRAF6 showed no decrease in the 
phosphorylation levels of AKT or ERK (Fig. 5A). 
Indeed, it appears that TRAF2 signaling 
negatively regulates PI3K/AKT and 
RAS/RAF/MEK/ERK pathways since there is 
increased phosphorylation of AKT and ERK in the 
absence of TRAF2 (Fig. 5A). In addition, long-
term expression of TRAF2 and TRAF6 blocking 
peptides does not affect AKT and ERK activity or 
cellular proliferation relative to the peptide 
controls (Figs. 5B-C).  Furthermore, it appears 
that TRAF2 knockdown (Fig 5A) or T2pep 
expression (Fig 5C) leads to decreased NIK kinase 
stability.  This finding is consistent with recent 
studies showing that RP3 promotes the 
stabilization of NIK to activate the canonical 
pathway of NF-κB (23).  Together these findings 
suggest that RET/PTCs induce a TRAF-dependent 
proinflammatory program in thyroid cells and this 
pathway is independent of PI3K/AKT and 
RAS/BRAF/MEK/ ERK activity.   
TRAF-deficient RP3 mutants maintain 
transforming properties.  Our data indicate that the 
TRAF-mediated pathway is spatially and 
functionally distinct from the PI3K/AKT or 
RAS/BRAF/MEK/ERK pathways.  Previous 
results have reported that point mutations within 
RAS or BRAF are sufficient to drive 
transformation of thyroid follicular cells (8).  
Based on our results above, we hypothesized that 
disrupting the TRAF pathway should have little to 
no impact on transformation.  To test this 
prediction, we examined whether the TRAF-
deficient mutants were capable of maintaining 
hormone independent growth.  In accordance with 
our observation that TRAF-deficient mutants 
maintained ERK and AKT activity, PCCL3 cells 
stably transduced with RP3Y478F, RP3T6mut, and 
RP3T2mut demonstrated hormone-independent 
growth comparable to RP3-transduced cells (Fig 
5D).  We further examined the ability of the 
TRAF-deficient mutants to promote anchorage-
independent growth.  NIH-3T3 cells were 
transduced with GFP-tagged retroviral constructs 
encoding wild-type or mutated RP3, sorted for 
GFP expression, and examined for colony growth 
in soft agar.  After 20 days of growth, the colonies 
were stained with crystal violet (Fig. S2) or 
photographed for measurement of colony size 
(Figs. 6A-B).  Most notably, the TRAF-deficient 
mutants, RP3T6mut and RP3T2mut induced colonies 
in size and number comparable to wild type RP3 
(Figs. 6A-B).  In contrast, RP3K284M, RP3Y431F, and 
RP3Y588F produced little to no colonies.  We 
confirmed that the lack of colony formation was 
not due to loss of gene expression (Fig. S3).   
Interestingly, the Y478 mutation resulted in 
transductants with compromised transformation 
properties compared with RP3WT (Figs. 6A-B).   
The lack of inflammatory cytokine production 
by RP3T6mut and RP3T2mut transfectants may limit 
their capacity to form tumors in vivo due to the 
lack of induced stromal support (49).  To test this 
notion, immunodeficient RAG-/- mice were 
subcutaneously injected with the NIH3T3 
transductants described above and monitored for 
tumor growth.  Fig. S6 shows that mice injected 
with RP3WT, RP3T6mut, or RP3T2mut transfectants 
rapidly developed palpable tumors after 13 days, 
while mice injected with NIH3T3 expressing GFP 
alone showed no tumor growth.  Mice that 
received RP3K284M or RP3Y588F cells did not grow 
significantly measurable tumors.  Interestingly it 
appears that the RP3T6mut transductants produced 
smaller tumors which may reflect the smaller 
colony size in Fig. 6B, a decreased influx of innate 
cells, or decreased stromal support and 
angiogenesis.  Further investigation that includes 
immunocompetent mice and increased animal 
numbers may allow for more detailed insight into 
the role that an intrinsic TRAF pathway plays on 
in vivo tumor progression.  In summary, the results 
indicate that RET/PTC-induced TRAF-mediated 
proinflammatory cytokine production is not 
required for cellular transformation driven by the 
PI3K/AKT and RAS/BRAF/MEK/ERK pathways.   
 
DISCUSSION 
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The unusual pleiotropic signaling properties of 
the RET/PTC oncogenes (14, 24, 34) provide an 
attractive model for studying the mechanistic 
relationships between oncogene-induced cellular 
transformation and proinflammatory pathways.  
RET/PTC translocation is thought to be one of the 
earliest events in the initiation of papillary thyroid 
cancer (9, 50) and ectopic pro-inflammatory 
mediators have been presumed to contribute to the 
cellular transformation process (2, 3), but this has 
not been formally tested for this cancer type.  We 
report here that TRAF-mediated cytokine 
induction and cellular transformation are 
functionally distinct in neoplastic thyrocytes, a 
finding that will enable a finer resolution of the 
components necessary to drive cancer progression.  
These data also point to one explanation for why 
oncogenes such as mutant RAS or BRAF do not 
exhibit the same degree of immunostimulatory 
phenotype and progress along different 
pathologies despite utilizing the same 
transforming pathways as RET/PTC-based tumors.  
Although stimulatory crosstalk between the 
RAS/AKT and NF-κB pathways has been 
suggested for lung epithelial cell tumorigenesis 
(51), we did not observe positive feedback 
mechanisms in our experimental systems. If 
anything, TRAF2 mediated signaling appears to 
suppress the AKT and ERK signaling pathways 
(Fig. 5A). This is in accordance with the 
observation that TRAF6 negatively regulates PI3K 
activity during T cell activation (52).  Additionally 
the signaling dichotomy we demonstrate here has 
recently been shown for MIG-6 tumor suppressor 
expression in PTC.  These studies demonstrate that 
MIG-6 overexpression in PTC tumor samples or 
the TPC-1 cell line activates NF-κB and inhibits 
ERK phosphorylation.  Conversely knockdown of 
MIG-6 decreased NF-κB nuclear localization and 
enhanced ERK activity (53). 
PTC rarely harbors coexisting RET/PTC, 
RAS, and/or BRAF mutations suggesting that 
there is limited functional complementation 
between these oncogenes with respect to thyroid 
tumor initiation/progression (54-56).  The 
experiments reported here demonstrate that 
RET/PTC-induced TRAF-mediated inflammation 
is not required for transformation.  Evidently only 
the PI3K/AKT and RAS/BRAF/MEK/ERK 
pathways are required to establish and maintain 
follicular cell transformation (57), while the 
inflammatory pathway that is unique to RET/PTC 
translocation may serve to modulate the tumor 
environment.  This conclusion is supported by 
recent evidence demonstrating that the MIG-6 
tumor suppressor expression correlates directly 
with increased NF-κB activity and inversely with 
tumor recurrence, survival, and oncogenic BRAF 
mutations (53, 58).  
Other studies have demonstrated functional 
separation in other cell types such as fibroblasts. 
For instance, the NF-κB members, p65 (Rel A) 
and c-REL, are not required for RAS-mediated 
transformation in fibroblasts, although p65 and c-
REL signaling can potentiate anchorage 
independent growth (59).  Furthermore, our 
studies showed that blockade of MEK/ERK and 
PI3K/AKT actually enhances inflammatory 
cytokine production from thyroid papillary 
carcinoma, compatible with the published finding 
that oncogenic RAS blocks TNF-induced NF-κB 
signaling (60). 
Our investigation has revealed that TRAFs 
associate with RP3 and activate an inflammatory 
program that is independent from the PI3K/AKT 
and RAS/BRAF/MEK/ERK pathways.  TRAF2 
and TRAF6 appear to associate independently of 
kinase action (as observed with RP3K284M), while 
pro-inflammatory TRAF complexes are formed 
only upon a catalytically active conformational 
change of the kinase domain (as observed with 
RP3WT).  This type of interaction has been 
described for TGFβR in which wild type, kinase 
dead, and constitutively active TGFβR, all 
associate with TRAF6 (61).  Since RET/PTC is 
constitutively expressed in transformed cells, it is 
possible that RET:TRAF complexes will be 
present at all times leading to aberrant regulation 
of NF-κB.  This is distinct from the conditional 
activation observed with RET and its ligand 
GDNF under physiological conditions.  A general 
model of RET/PTC signaling, based on our 
results, is depicted in Fig. 7. A key feature is the 
association of TRAF2 and TRAF6 only after 
dimerization of RP3.  This is similar to TNFR 
family members BAFFR and CD40 which exhibit 
TRAF association only after ligand binding (62).  
In the case of RP3, conversion to the active 
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dimeric conformation (Fig. 7) may result in 
increased surface exposure of the TRAF-binding 
segments.  The observation that mutation of the 
putative TRAF6 binding site (RP3T6mut) resulted in 
reduced association with both TRAF2 and TRAF6 
(Figs. 3D&F) was also of interest.  TRAF2 often 
forms hetero-complexes with other TRAF family 
members (63). Therefore it is possible that TRAF2 
interacts directly with TRAF6 at this site or that 
this location contains binding motifs for both 
TRAF2 and TRAF6.  This type of TRAF2:TRAF6 
interaction has also been described for the 
proinflammatory receptor CD40 (64).   
We observed that both TRAF2 and TRAF6 
associate with RP3 independent of the Y588 site.  
Previous reports suggest that proinflammatory 
cytokine production initiates `via a Y588-
dependent signaling cascade (14, 25). It is 
interesting that in the absence of TRAF mediated 
pathways, we observed the greatest difference in 
MCP1 production compared with other cytokines 
whereas MCP1 was the least affected using Y588 
mutants (25).  Further investigation is required to 
assess the relative involvement of a TRAF-, AKT-
, and ERK-independent/Y588-dependent pathway 
in cytokine induction.  The RAS/BRAF pathway 
has also been implicated in secretion of IL-24, IL-
8, and other chemokines (65, 66), it is possible that 
the quality of the proinflammatory cytokine 
induction from a RAS-mediated pathway may lead 
to a more immune-suppressive/tumor-promoting 
environment.  While the additional RET/PTC-
induced TRAF-mediated pathway skews the 
cytokine profile towards a more 
immunostimulatory phenotype.  This change in 
cytokine profile may strongly contribute to the 
autoimmune thyroiditis that is associated with 
RET/PTC-expressing tumors.  
Activation of NF-κB by RET/PTC involves 
members of the classical and alternative pathways 
through the stabilization of NIK kinase (23).  NIK 
was originally cloned and described as a binding 
partner of TRAF2 through two-hybrid screening of 
a human B cell cDNA library (67).  Subsequently, 
TRAF2 and TRAF6 were shown to activate NF-
κB by inhibiting the constitutive proteolytic 
degradation of NIK (63, 67-70).  Additionally, the 
deregulated constitutive expression of NIK results 
in a predominant classical activation of NF-κB 
and production of proinflammatory mediators in 
vivo (71).  In our studies we observed that 
knockdown of either TRAF2 or TRAF6 in PTC 
abrogates the accumulation of NIK (Fig. 5), 
suggesting that RET/PTC activation of TRAF 
complexes mediates a pro-inflammatory state 
through NIK kinase.  The observation that TRAF 
knockdown results in depletion of NIK kinase, 
with no impact on phosphorylation of AKT and 
ERK argues further for functional divergence of 
the inflammatory and oncogenic pathways. 
Here we propose the possibility that 
RAS/BRAF and/or PI3K/AKT pathways are 
required for cellular transformation and that the 
additional inflammatory property of RET/PTCs 
shapes the formation of a relatively indolent tumor 
by providing an immunostimulatory/tumor-
suppressive inflammatory microenvironment.  
This could occur by several potentially 
cooperative mechanisms: (a). Autocrine 
stimulation by cytokines may retard tumor growth.  
RET/PTC-expressing human thyroid cell lines and 
thyroids from transgenic animals show substantial 
up-regulation of many inflammatory mediators 
including IL1α, IL1β, IL6, TNFα, IL8, GMCSF, 
and MCP1 (14, 24, 34) and it has been reported 
that many of these cytokines can inhibit thyroid 
tumor cell growth (72).  (b). The composition of 
the infiltrate itself may lack the factors required 
for progression.  More aggressive carcinomas that 
harbor RAS or BRAF mutations display a heavy 
influx of inflammatory cells but these tend to be 
immunosuppressive in nature (22).  Indeed, tumor-
associated macrophages (TAMs) generally exhibit 
alternate (“M2”) activation and are mitogenic, 
angiogenic, and pro-metastatic through 
mechanisms that include IL10, TGFβ, VEGF, and 
matrix metalloprotease secretion, respectively 
(73). In contrast, the lymphocytic infiltration 
associated with indolent PTC is usually 
characterized by a Th1 phenotype (74, 75) that is 
not conducive to the production of 
immunosuppressive TAMS (73) and infiltrating 
TAMs are rarely found in less aggressive well-
differentiated thyroid carcinoma (22).  (c). The 
proinflammatory environment may cause a break 
in peripheral tolerance and aid the adaptive arm in 
controlling/eliminating the tumor.  For example, 
CXCR4, STAT1, CIITA and MHC Class II are 
also up-regulated by RET/PTC expression in 
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human thyroid cells in vivo (34, 76, 77). Together 
these molecules provide signals for leukocyte 
migration, dendritic cell differentiation, and 
antigen presentation.  Consistent with this,  tumors 
derived from RP3 transgenic animals are capable 
of rapid growth in SCID mice but not 
immunocompetent hosts (78).   
Clinically, PTCs harboring active RET 
translocations are found co-incident with 
autoimmune Hashimoto’s thyroiditis (HT) (16-
21).  This longstanding observation has led to the 
hypothesis that HT is a risk factor for PTC and, 
furthermore, that HT is a precancerous condition 
(2, 3).  For the various reasons discussed, we 
suggest the converse, that the autoimmune 
component is the result, rather than the cause of 
RET/PTC transformation.  Activation of innate 
and adaptive immunity via the TRAF signaling 
component of RET/PTC would explain the intense 
and persistent peritumoral lymphocytic infiltration 
and indolent growth that is often associated with 
PTC.   The TRAF-mediated proinflammatory 
signaling linked to RET/PTC may also help 
explain the concurrent expression of RET/PTC 
(21) and the better overall prognosis of thyroid 
cancer in HT patients (79).   
Although data indicate that TRAF-mediated 
pathways are not required for early events in 
transformation, the question remains whether these 
same TRAF-mediated pathways are required for 
later stages of tumor progression.  Indeed the 
RP3T6mut, or RP3T2mut tumors were smaller than the 
comparable RP3wt tumors suggesting that 
inflammatory mediators may contribute to, but are 
not necessary for, tumor growth.  Accordingly, the 
lack of these cytokines may limit the recruitment 
of stromal elements and suppress the likelihood of 
growth variants (80).   Consistent with this, 
TRAF-mediated NF-κB activation is known to 
control cell viability and angiogenesis in many 
tumor types (1). 
Elucidating the influence of RET/PTC induced 
inflammation on thyroid tumorigenesis may lead 
to more effective therapeutic strategies for PTC.  
For example, following surgery, any residual 
RET/PTC harboring tumors may be best 
approached by targeting only the PI3K/AKT- and 
RAS-mediated pathways, while preserving the 
inflammatory component.  Conversely, induction 
of a “RET/PTC-like” TRAF signaling pathway 
within the more aggressive PTCs that feature only 
oncogenic RAS and BRAF mutations may convert 
such tumors to a more benign form.  Alternatively, 
if TRAF-mediated NF-κB pathways are found to 
play a greater role in angiogenesis and escape 
during progression then the therapeutic strategy 
should be to knockdown both proinflammatory 
and oncogenic arms of RET/PTC signaling.  
Experiments are currently underway to test these 
possibilities. 
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FIGURE LEGENDS 
 
Fig. 1.  Inhibitors of PI3K or MEK do not inhibit RP3-mediated proinflammatory cytokine transcription.  
(A)  PCCL3 cells were transiently transfected with RP3WT or RP3K284M in the presence of 0.1% DMSO 
alone, 10 µM of LY294002 or 10 µM of U0126 for 48 hr and cells were lysed for total RNA followed by 
reverse transcription and PCR for rat specific gene products.  (B) PCCL3 cells were treated as in (A) and 
harvested at 48 hr for total protein and western blot analysis.  (C)  TPC-1 cells were treated for 48 hr with 
0.1% DMSO alone, 10 µM of LY294002 or 10 µM of U0126 and subsequently harvested for total RNA 
followed by reverse transcription and PCR for human specific gene products.  (D) TPC-1 cells were 
treated as in (C) and harvested at 48 hr for total protein and western blot analysis.   (A-D) Data 
representative of two independent experiments. RevT: Reverse transcriptase; LY: LY294002; U0: U0126 
Fig. 2.  (A-B) RP3Y478F exhibits reduced MCP-1 expression and maintains AKT and ERK activation.  (A) 
PCCL3 cells were transiently transfected with Rc/CMV vector alone, RP3WT or RP3YF mutants for 48 hr 
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and cells were lysed, total RNA extracted and RNA reverse transcribed and cDNA amplified using rat 
GAPDH and MCP1 specific primers.  Error bars indicate SEM from at least three independent 
experiments. (B) PCCL3 cells were transiently transfected with MSCV.IRES.GFP vector alone, RP3WT, 
RP3K284M, or RP3Y588F/Y622F mutants for 48 hr and cells were lysed, total RNA extracted and RNA reverse 
transcribed and cDNA amplified using rat GAPDH and MCP1 specific primers. (C)  Representative 
western blot of two individual experiments of PCCL3 cells that were treated as in (A) and harvested at 48 
hr for total protein.    
Fig. 3.  RP3 associates with TRAF2 and TRAF6 in a dimer-dependent and kinase-independent manner.  
(A) Schematic representation of RP3WT, RP3K284M, and truncation mutants.  (B-F) 293T cells were 
transiently transfected with GFP, RP3WT or RP3K284M, or truncation (∆) mutants for 48 hr, lysed, and 
subsequently harvested for immunoprecipitation using an anti-RET.51 specific antibody.  
Immunoprecipitated protein was subjected to western blot analysis using antibodies specific for TRAF2, 
TRAF6, RET or Actin.  (G) TPC-1 cell were lysed and subsequently harvested for immunoprecipitation 
using an anti-RET.51 specific antibody.  Immunoprecipitated protein was subjected to western blot 
analysis using antibodies specific for TRAF2, TRAF6, RET or Actin.  Representative of at three 
independent experiments..  IP: immunoprecipitation; UB: unbound fraction;  hIgG: goat IgG heavy chain.  
Fig. 4.  Knockdown of TRAF2 and TRAF6 abrogates cytokine expression.  (A-B) TPC-1 cells were 
transfected with non-targeting control, TRAF2, or TRAF6 siRNA and harvested after 48 hours for total 
RNA followed by reverse transcription and PCR using human GAPDH, MCP1, IL6, IL8, TNF, GM-CSF, 
TRAF2, TRAF6, and RET/PTC1 specific primers.  (A) Representative experiment of cytokine transcript 
induction of at least 3 individual experiments.  (B) Graphs are represented as densitometric analysis of 
band intensity relative to GAPDH and the fold induction of that ratio over scrambled siRNA control.  
Error bars indicate SD of samples run in triplicate, in three independent experiments. (C)   MCP1 
secretion was measured on day 4 by ELISA using culture supernantants derived from TPC-1 cells 
transfected with scrambled control, TRAF2, or TRAF6 siRNAs treated on day 0 and retreated on day 2.  
(D) TPC-1 cells were transduced with MSCV.IRES.RFP constructs expressing T2 and T6 binding motifs 
and their peptide controls.  Following selection for RFP, cells were harvested for total RNA followed by 
reverse transcription and PCR using human GAPDH and MCP1 specific primers.   (E) PCCL3 cells were 
stably transduced with RP3WT or RP3YF mutants and after a month of passage in culture, cells were 
plated overnight and lysed for total RNA followed by reverse transcription and PCR with rat GAPDH and 
MCP-1 specific primers.  Represented as densitometric measurements of band intensity relative to 
GAPDH and the fold induction of that ratio over RP3.  (C-E) Error bars indicate SD of samples run in 
duplicate, in two independent experiments. Cntl: non-targeting siRNA control; T2: TRAF2; T6: TRAF6 
Fig. 5.  Disruption of TRAF2 and 6 pathways does not inhibit AKT and ERK pathways.  (A)  TPC-1 cells 
were transfected with scrambled control, TRAF2, or TRAF6 siRNA and re-treated with siRNA on day 2 
and on day 4 were harvested for western blot analysis.  (B) TPC-1 cells were transduced with 
MSCV.IRES.RFP constructs expressing T2 and T6 binding motifs and their peptide controls.  Following 
selection for RFP, cells were harvested for western blot analysis.  (C) Cell proliferation assay of 
transduced TPC-1cells from (B) that were plated at 1000 cells/well in 96-well culture dishes and counted 
daily.  (D) ERK-dependent hormone-independent cell proliferation assay of transduced PCCL3cells 
expressing wild type RP3 and mutants.  Cells were plated at 1000 cells/well in 96-well culture dishes in 
the absence of  6 hormones (TSH, insulin, Gly-His-Lys, somatostatin, apo-transferin, and hydrocortisone 
) and counted daily.  Data are representative of three independent experiments.  Cntl: non-targeting 
siRNA control; T2: TRAF2; T6: TRAF6 
Fig. 6.  TRAF-deficient RP3 mutants maintain transforming activity.   (A) Representative photographs of 
anchorage-independent colony growth of  NIH-3T3 cells stably transduced with RP3WT and mutants used 
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for the analysis in (B).  (B) Number of colonies counted from a defined grid that were produced from 
NIH-3T3 transductants as in (A) that were greater than 100 µm in length and averaged over triplicate 
wells.  The table below the graph represents the average colony length and standard deviation of the 
triplicate wells.  Representative of two independent experiments.    
Fig. 7.  Model of RET/PTC-mediated TRAF activation.  
ΡΕΤ/ΠΤΧ διµερσ εξηιβιτ α γρεατερ αφφινιτψ φορ ΤΡΑΦ2 ανδ ΤΡΑΦ6 τηαν ΡΕΤ/ΠΤΧ µονοµερσ.  
Τηε ΤΡΑΦ ιντεραχτιον ωιτη ΡΕΤ/ΠΤΧ δοεσ νοτ ρεθυιρε αν αχτιϖε χονφορµατιον οφ τηε κινασε 
δοµαιν.  Ηοωεϖερ, ΤΡΑΦ αχτιϖατιον δοεσ ρεθυιρε αν αχτιϖε κινασε δοµαιν χονφορµατιον ωηι
χη µοστ λικελψ ινδυχεσ ΤΡΑΦ ολιγοµεριζατιον το προµοτε ΝΙΚ ανδ ΝΦ−κB-mediated 
proinflammatory signaling.  The RET/PTC:TRAF:NIK:NF-κB pathway is functionally distinct from 
Y588-mediated RAS and PI3K signaling cascades that promote transformation. 
  
 
